James Dahlman is a biomedical engineer who works at the intersection of nanotechnology, molecular biology, and genomics. He is an associate professor at Georgia Institute of Technology and Emory School of Medicine, and the director of the Lab for Precision Therapies. His lab designs drug delivery vehicles that target RNA and other nucleic acids to cells in the body, and uses DNA barcodes to screen thousands of nanoparticles in vivo. He has applied his technology to treat diseases such as heart disease, cancer, inflammation, and pulmonary hypertension. He has also developed new tools for gene editing using CRISPR-Cas9. James has received numerous awards for his research, including the McCamish Foundation Early Career Professorship. His work has been translated via Guide Therapeutics, which was spun out of Georgia Tech and acquired by Beam Therapeutics. He is also a passionate educator and mentor who loves to share his enthusiasm for science with students and the public.